



## Press Release

# Bio-Rad Expands Range of Quality Controls for Abbott Clinical Diagnostics Platforms

HERCULES, Calif.— November 16, 2022 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced an expanded portfolio of independent quality controls (QC) products, now including IntelliQ and Liquichek compact vials, for the Abbott Alinity ci-series integrated clinical chemistry and immunoassay testing instruments.

"We are pleased to expand our offering of independent quality controls for the Abbott Alinity ci-series platforms," said Dara Wright, EVP, and President of Bio-Rad's Clinical Diagnostics Group. "Bio-Rad's barcoded tubes and vials, combined with robust data management software, offer a flexible QC solution for a complete customer choice on Abbott Alinity ci platforms to streamline their QC workflow and enhance user experience."

Bio-Rad is a global leader in quality control products, offering an extensive range of quality controls covering analytes for immunoassay, chemistry, cardiac assessment, immunology, diabetes, coagulation, hematology, blood gas, drugs-of-abuse, and infectious disease testing. The company's QC data management solutions connect large peer groups of test systems and assay methods to the company's Unity Interlaboratory Program, enabling labs to compare their results in real time with over 29,000 other labs worldwide.

To learn more about Bio-Rad's complete QC workflow solutions, please visit:

<http://www.qcnet.com/Abbott>

*BIO-RAD, IntelliQ, and Liquichek are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.*

## About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 8,200 employees worldwide and \$2.9 billion in revenues in 2021. For more information, please visit [bio-rad.com](http://bio-rad.com).

## **Forward-Looking Statements**

*This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.*

### **Media Contact:**

Anna Gralinska  
Corporate Communications  
510-741-6643  
[cc@bio-rad.com](mailto:cc@bio-rad.com)